Doxorubicin-Loaded Gold Nanoarchitectures as a Therapeutic Strategy against Diffuse Intrinsic Pontine Glioma.
DIPG
doxorubicin
gold nanoparticles
nanoarchitectures
orthotopic animal models
paediatric brain tumours
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
13 Mar 2021
13 Mar 2021
Historique:
received:
15
02
2021
revised:
09
03
2021
accepted:
09
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
Diffuse Intrinsic Pontine Gliomas (DIPGs) are highly aggressive paediatric brain tumours. Currently, irradiation is the only standard treatment, but is palliative in nature and most patients die within 12 months of diagnosis. Novel therapeutic approaches are urgently needed for the treatment of this devastating disease. We have developed non-persistent gold nano-architectures (NAs) functionalised with human serum albumin (HSA) for the delivery of doxorubicin. Doxorubicin has been previously reported to be cytotoxic in DIPG cells. In this study, we have preclinically evaluated the cytotoxic efficacy of doxorubicin delivered through gold nanoarchitectures (NAs-HSA-Dox). We found that DIPG neurospheres were equally sensitive to doxorubicin and doxorubicin-loaded NAs. Colony formation assays demonstrated greater potency of NAs-HSA-Dox on colony formation compared to doxorubicin. Western blot analysis indicated increased apoptotic markers cleaved Parp, cleaved caspase 3 and phosphorylated H2AX in NAs-HSA-Dox treated DIPG neurospheres. Live cell content and confocal imaging demonstrated significantly higher uptake of NAs-HSA-Dox into DIPG neurospheres compared to doxorubicin alone. Despite the potency of the NAs in vitro, treatment of an orthotopic model of DIPG showed no antitumour effect. This disparate outcome may be due to the integrity of the blood-brain barrier and highlights the need to develop therapies to enhance penetration of drugs into DIPG.
Identifiants
pubmed: 33805713
pii: cancers13061278
doi: 10.3390/cancers13061278
pmc: PMC7999568
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Tour de Cure
ID : Pioneering Cancer Research Grant
Références
J Control Release. 2014 Sep 28;190:31-2
pubmed: 25356469
J Neurosurg Pediatr. 2018 Sep;22(3):288-296
pubmed: 29856296
J Control Release. 2018 Aug 10;283:143-150
pubmed: 29864474
Oncotarget. 2018 Jan 8;9(7):7541-7556
pubmed: 29484131
Nanoscale Res Lett. 2019 Apr 18;14(1):138
pubmed: 31001703
Cancers (Basel). 2020 Apr 25;12(5):
pubmed: 32344838
J Colloid Interface Sci. 2021 Jan 15;582(Pt B):1003-1011
pubmed: 32927167
Curr Top Med Chem. 2015;15(16):1605-13
pubmed: 25877087
Curr Cancer Drug Targets. 2013 May;13(4):362-78
pubmed: 23517593
J Control Release. 2019 Feb 10;295:130-139
pubmed: 30537486
Am J Clin Oncol. 1997 Jun;20(3):263-5
pubmed: 9167750
Cancer Chemother Pharmacol. 2011 Sep;68(3):721-31
pubmed: 21161529
Front Oncol. 2015 Jun 30;5:147
pubmed: 26175967
Nat Genet. 2014 May;46(5):444-450
pubmed: 24705251
Neuro Oncol. 2020 Jan 11;22(1):139-151
pubmed: 31398252
Molecules. 2017 Aug 31;22(9):
pubmed: 28858253
Nanomedicine. 2018 Aug;14(6):1787-1795
pubmed: 29778890
Mater Sci Eng C Mater Biol Appl. 2021 Jan;118:111357
pubmed: 33254977
Ultrasound Med Biol. 2016 Jul;42(7):1499-511
pubmed: 27126236
ACS Omega. 2018 Sep 30;3(9):11796-11801
pubmed: 30320273
J Korean Neurosurg Soc. 2018 May;61(3):343-351
pubmed: 29742880
Mol Cancer Ther. 2018 May;17(5):1012-1023
pubmed: 29491149
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Adv Radiat Oncol. 2019 Mar 30;4(3):520-531
pubmed: 31360809
Toxicol In Vitro. 2017 Aug;42:114-122
pubmed: 28414162
Int J Pharm. 2007 Aug 16;341(1-2):207-14
pubmed: 17478065
J Clin Oncol. 2011 Oct 20;29(30):3999-4006
pubmed: 21931021
Nanomedicine. 2012 Oct;8(7):1133-42
pubmed: 22349099
Pharmaceutics. 2018 Dec 22;11(1):
pubmed: 30583524
Int J Mol Sci. 2018 Jul 06;19(7):
pubmed: 29986450
Eur J Pharm Sci. 2018 Mar 1;114:199-209
pubmed: 29269322
J Neurooncol. 2019 Jan;141(2):253-263
pubmed: 30446898
Beilstein J Nanotechnol. 2019 Aug 14;10:1707-1715
pubmed: 31501742
Br J Cancer. 2007 Aug 6;97(3):322-6
pubmed: 17609666
Nanotoxicology. 2018 Oct;12(8):914-922
pubmed: 30132360
Front Oncol. 2018 Jul 03;8:239
pubmed: 30018882
Pharmaceutics. 2020 Apr 27;12(5):
pubmed: 32349240
J Control Release. 2017 Mar 28;250:77-85
pubmed: 27742444
Sci Adv. 2016 Dec 23;2(12):e1600516
pubmed: 28028533
Pediatr Blood Cancer. 2012 Apr;58(4):489-91
pubmed: 22190243
Childs Nerv Syst. 1999 Oct;15(10):545-53
pubmed: 10550585
Int J Biol Macromol. 2019 Feb 1;122:538-548
pubmed: 30389527
Curr Neuropharmacol. 2017;15(1):104-115
pubmed: 26903150
Nature. 2019 Sep;573(7775):539-545
pubmed: 31534222
J Control Release. 2018 Jul 10;281:42-57
pubmed: 29753958
Int J Nanomedicine. 2017 Aug 09;12:5613-5629
pubmed: 28848341
Nat Commun. 2021 Feb 12;12(1):971
pubmed: 33579942
Neurosurgery. 1992 Jan;30(1):30-4
pubmed: 1738452
Int J Pharm. 2017 Jan 30;517(1-2):168-174
pubmed: 27956195
ACS Appl Mater Interfaces. 2018 Dec 19;10(50):43411-43428
pubmed: 30508486
Soft Matter. 2020 Aug 19;16(32):7492-7502
pubmed: 32724986
Eur J Pharm Biopharm. 2017 Aug;117:324-332
pubmed: 28478161
Int J Pharm. 2019 Jun 10;564:145-152
pubmed: 30978484
Clin Cancer Res. 2018 Nov 15;24(22):5645-5657
pubmed: 30061363
Nature. 2017 Sep 28;549(7673):533-537
pubmed: 28959975
Sci Rep. 2017 Mar 16;7:44735
pubmed: 28300219
PLoS One. 2017 Jan 4;12(1):e0169485
pubmed: 28052119
PLoS One. 2014 Jul 29;9(7):e103736
pubmed: 25072631
Nat Med. 2013 Dec;19(12):1584-96
pubmed: 24309662
Nat Nanotechnol. 2018 Sep;13(9):777-785
pubmed: 30190620
J Neurosurg Pediatr. 2011 Jul;8(1):97-102
pubmed: 21721895
Curr Neuropharmacol. 2017;15(1):116-128
pubmed: 27306036
Int J Pharm. 2019 Mar 25;559:360-372
pubmed: 30721725
J Control Release. 2018 Jul 10;281:29-41
pubmed: 29753957